The survey also showed that high drug costs and artificial intelligence are topmost among the respondent’s concerns.

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

In this new role, Flaster will lead Cigna Healthcare’s clinical organization, focusing on initiatives to improve customer ...

Panelists discuss the potential role of emerging treatments in the progressive pulmonary fibrosis (PPF) landscape if approved ...

As the nation is again under the reigns of a Trump administration and a Republican-led Congress, debates on reducing spending ...

Panelists discuss the key gaps and unmet needs in current management strategies for progressive pulmonary fibrosis (PPF) and ...

A panelist discusses how she proactively addresses safety concerns about neurokinin-targeted therapies through evidence-based ...

A monthly 10 mg/mL maintenance dose of Leqembi had the same effects on mild Alzheimer’s symptoms as biweekly dose, research ...

The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

As with PTSD, people develop acute stress disorder after exposure to traumatic events. The key difference in the diagnostic ...

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...